troglitazone has been researched along with Arteriosclerosis in 28 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This finding suggests that primary treatment of insulin resistance could prevent the development of atherosclerosis by improving endothelial dysfunction." | 5.31 | Troglitazone improves endothelial dysfunction in patients with insulin resistance. ( Daida, H; Hoshi, S; Iwama, Y; Mokuno, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Troglitazone, a newly introduced insulin sensitizer, has been implicated in prevention and treatment of atherosclerotic cardiovascular disease especially associated with type 2 diabetes mellitus and insulin resistance." | 4.80 | [Cardiovascular effects of the thiazolidinedione troglitazone]. ( Kuzuya, H; Nakano, T; Yamada, K, 2000) |
| " In the present study, we used Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which exhibit hypertension, obesity, severe hyperglycemia and hypertriglyceridemia, and are thus considered an animal model of atherogenic disease, to test the effects of oral administration of troglitazone (200 mg/kg) on renal klotho mRNA expression and endothelial function." | 3.71 | Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. ( Kanai, H; Kurabayashi, M; Kuro-o, M; Nabeshima, Y; Nagai, R; Nakamura, T; Saito, Y; Sumino, H; Takeda, S; Yamagishi, T, 2001) |
| "The thiazolidinedione analogue troglitazone is an antidiabetic agent that improves insulin resistance in rodents and humans." | 3.70 | Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. ( Funahashi, T; Kihara, S; Matsuzawa, Y; Ouchi, N; Shinohara, E; Tamura, R; Yamashita, S, 1998) |
| " We tested the hypothesis that troglitazone, which improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subjects and patients with type 2 diabetes, would also lower circulating PAI-1 antigen concentrations and activity." | 3.70 | Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. ( Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG, 2000) |
| "Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease." | 2.71 | Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003) |
| "Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications." | 2.70 | Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. ( Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A, 2001) |
| "This finding suggests that primary treatment of insulin resistance could prevent the development of atherosclerosis by improving endothelial dysfunction." | 1.31 | Troglitazone improves endothelial dysfunction in patients with insulin resistance. ( Daida, H; Hoshi, S; Iwama, Y; Mokuno, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| "Troglitazone may be useful in the treatment of insulin resistance as well as of hypertensive vascular diseases." | 1.31 | Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. ( Chikara, S; Fukuda, N; Hu, WY; Kanmatsuse, K; Kishioka, H; Nakayama, M; Teng, J, 2002) |
| "Since WHHL rabbits show hyperinsulinemia and insulin resistance, we administered troglitazone (100 mg/kg), an insulin action enhancer, pravastatin sodium (50 mg/kg), an HMG CoA reductase inhibitor, and a combination of both drugs to 2-month-old WHHL rabbits for 32 weeks." | 1.30 | Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. ( Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 21 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iida, KT | 1 |
| Kawakami, Y | 1 |
| Suzuki, M | 1 |
| Shimano, H | 2 |
| Toyoshima, H | 1 |
| Sone, H | 1 |
| Shimada, K | 2 |
| Iwama, Y | 2 |
| Watanabe, Y | 2 |
| Mokuno, H | 2 |
| Kamata, K | 1 |
| Yamada, N | 2 |
| Varo, N | 1 |
| Vicent, D | 1 |
| Libby, P | 2 |
| Nuzzo, R | 1 |
| Calle-Pascual, AL | 1 |
| Bernal, MR | 1 |
| Fernández-Cruz, A | 1 |
| Veves, A | 1 |
| Jarolim, P | 1 |
| Varo, JJ | 1 |
| Goldfine, A | 1 |
| Horton, E | 1 |
| Schönbeck, U | 1 |
| Xiang, AH | 1 |
| Peters, RK | 1 |
| Kjos, SL | 1 |
| Ochoa, C | 1 |
| Marroquin, A | 1 |
| Goico, J | 1 |
| Tan, S | 1 |
| Wang, C | 1 |
| Azen, SP | 1 |
| Liu, CR | 1 |
| Liu, CH | 1 |
| Hodis, HN | 1 |
| Buchanan, TA | 1 |
| Tanaka, T | 2 |
| Fukunaga, Y | 2 |
| Itoh, H | 2 |
| Doi, K | 2 |
| Yamashita, J | 2 |
| Chun, TH | 2 |
| Inoue, M | 2 |
| Masatsugu, K | 2 |
| Saito, T | 2 |
| Sawada, N | 2 |
| Sakaguchi, S | 1 |
| Arai, H | 1 |
| Nakao, K | 2 |
| Reamy, BV | 1 |
| Law, RE | 2 |
| Meehan, WP | 2 |
| Xi, XP | 1 |
| Graf, K | 1 |
| Wuthrich, DA | 1 |
| Coats, W | 1 |
| Faxon, D | 1 |
| Hsueh, WA | 2 |
| Cominacini, L | 2 |
| Garbin, U | 2 |
| Pastorino, AM | 1 |
| Campagnola, M | 2 |
| Fratta Pasini, A | 2 |
| Davoli, A | 2 |
| Rigoni, A | 1 |
| Lo Cascio, V | 2 |
| Foot, E | 1 |
| Sighieri, G | 1 |
| Sironi, AM | 1 |
| Ferrannini, E | 1 |
| Kihara, S | 1 |
| Ouchi, N | 1 |
| Funahashi, T | 1 |
| Shinohara, E | 1 |
| Tamura, R | 1 |
| Yamashita, S | 1 |
| Matsuzawa, Y | 1 |
| Marx, N | 2 |
| Sukhova, G | 1 |
| Murphy, C | 1 |
| Plutzky, J | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Shiomi, M | 1 |
| Ito, T | 1 |
| Tsukada, T | 1 |
| Tsujita, Y | 1 |
| Horikoshi, H | 2 |
| Pasceri, V | 1 |
| Wu, HD | 1 |
| Willerson, JT | 1 |
| Yeh, ET | 1 |
| Yamada, K | 1 |
| Kuzuya, H | 1 |
| Nakano, T | 1 |
| Hashimoto, T | 1 |
| Fujiwara, T | 1 |
| Kruszynska, YT | 1 |
| Yu, JG | 1 |
| Olefsky, JM | 1 |
| Sobel, BE | 1 |
| Glass, CK | 1 |
| Collins, AR | 1 |
| Kintscher, U | 1 |
| Jackson, S | 1 |
| Wakino, S | 1 |
| Noh, G | 1 |
| Palinski, W | 1 |
| Chen, Z | 1 |
| Ishibashi, S | 1 |
| Perrey, S | 1 |
| Gotoda, T | 1 |
| Kitamine, T | 1 |
| Tamura, Y | 1 |
| Okazaki, H | 1 |
| Yahagi, N | 1 |
| Iizuka, Y | 1 |
| Shionoiri, F | 1 |
| Ohashi, K | 1 |
| Harada, K | 1 |
| Nagai, R | 2 |
| Ghanim, H | 1 |
| Garg, R | 1 |
| Aljada, A | 1 |
| Mohanty, P | 1 |
| Kumbkarni, Y | 1 |
| Assian, E | 1 |
| Hamouda, W | 1 |
| Dandona, P | 1 |
| Sunayama, S | 1 |
| Sawano, M | 1 |
| Hoshi, S | 1 |
| Daida, H | 1 |
| Yamaguchi, H | 1 |
| Hosoda, K | 1 |
| Kook, H | 1 |
| Ueda, M | 1 |
| Chiba, Y | 1 |
| Ogita, T | 1 |
| Ando, K | 1 |
| Fujita, T | 1 |
| Hombach, V | 1 |
| Osende, JI | 1 |
| Badimon, JJ | 1 |
| Fuster, V | 1 |
| Herson, P | 1 |
| Rabito, P | 1 |
| Vidhun, R | 1 |
| Zaman, A | 1 |
| Rodriguez, OJ | 1 |
| Lev, EI | 1 |
| Rauch, U | 1 |
| Heflt, G | 1 |
| Fallon, JT | 1 |
| Crandall, JP | 1 |
| Yamagishi, T | 1 |
| Saito, Y | 1 |
| Nakamura, T | 1 |
| Takeda, S | 1 |
| Kanai, H | 1 |
| Sumino, H | 1 |
| Kuro-o, M | 1 |
| Nabeshima, Y | 1 |
| Kurabayashi, M | 1 |
| Marra, F | 1 |
| Pastacaldi, S | 1 |
| Fukuda, N | 1 |
| Hu, WY | 1 |
| Teng, J | 1 |
| Chikara, S | 1 |
| Nakayama, M | 1 |
| Kishioka, H | 1 |
| Kanmatsuse, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model[NCT00728286] | 90 participants (Actual) | Observational | 2008-10-31 | Completed | |||
| Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[NCT00728156] | Phase 4 | 90 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for troglitazone and Arteriosclerosis
| Article | Year |
|---|---|
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellit | 2000 |
Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.
Topics: Animals; Arteriosclerosis; Blood Coagulation Disorders; Cardiac Output; Cholesterol; Chromans; Endot | 2000 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
4 trials available for troglitazone and Arteriosclerosis
| Article | Year |
|---|---|
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas | 2003 |
Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
Topics: Adult; Arteriosclerosis; Carotid Arteries; Chromans; Diabetes Mellitus, Type 2; Disease Progression; | 2005 |
Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.
Topics: Analysis of Variance; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Doubl | 1998 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
19 other studies available for troglitazone and Arteriosclerosis
| Article | Year |
|---|---|
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mell | 2003 |
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.
Topics: Alitretinoin; Angioplasty, Balloon; Animals; Aorta; Arteriosclerosis; Binding, Competitive; Cell Lin | 2005 |
Preventing the progression of diabetes mellitus.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents; Inf | 2005 |
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Topics: Animals; Arteriosclerosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Movemen | 1996 |
Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells.
Topics: Arteriosclerosis; Cells, Cultured; Chromans; Copper; Diabetes Mellitus; Endothelium; Humans; Hypogly | 1997 |
Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells.
Topics: Aorta; Arteriosclerosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Culture | 1998 |
Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.
Topics: Arteriosclerosis; Blotting, Northern; Blotting, Western; Cell Line; Cells, Cultured; Chromans; Colla | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vess | 1999 |
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.
Topics: Animals; Arteriosclerosis; Cell Movement; Cells, Cultured; Chromans; Endothelium, Vascular; Humans; | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; G | 2000 |
Antiatherogenic effects of thiazolidinediones?
Topics: Animals; Arteriosclerosis; Cell Movement; Chromans; Diabetes Mellitus, Type 2; Dietary Fats; Humans; | 2001 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glu | 2001 |
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Blotting, Northern; Body Weight; | 2001 |
Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
Topics: Adult; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; C-Reactive Protein; Cell Nucleus; | 2001 |
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
Topics: Adult; Arteriosclerosis; Brachial Artery; Case-Control Studies; Chromans; Endothelium, Vascular; Glu | 2000 |
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Topics: Animals; Arteriosclerosis; Carotid Arteries; Cattle; Cell Division; Cells, Cultured; Chromans; Coron | 2001 |
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
Topics: Animals; Arteriosclerosis; Cattle; Cells, Cultured; Chromans; Drug Antagonism; Endothelium; Immunohi | 2001 |
Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.
Topics: Animals; Arteriosclerosis; Chromans; Endothelium, Vascular; Glucuronidase; Hypertension; Kidney; Klo | 2001 |
Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Arteriosclerosis; Cell Division; Cells, Cultured; Chromans; Depression, Che | 2002 |